X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DR. REDDYS LAB - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DR. REDDYS LAB SUN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.8 29.8 86.7% View Chart
P/BV x 3.8 2.9 129.3% View Chart
Dividend Yield % 0.6 0.9 65.8%  

Financials

 SUN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
DR. REDDYS LAB
Mar-17
SUN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8423,397 24.8%   
Low Rs5722,560 22.4%   
Sales per share (Unadj.) Rs131.6856.5 15.4%  
Earnings per share (Unadj.) Rs32.778.0 41.9%  
Cash flow per share (Unadj.) Rs38.0139.9 27.1%  
Dividends per share (Unadj.) Rs3.5020.00 17.5%  
Dividend yield (eoy) %0.50.7 73.7%  
Book value per share (Unadj.) Rs152.7739.8 20.6%  
Shares outstanding (eoy) m2,399.26165.74 1,447.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.43.5 154.5%   
Avg P/E ratio x21.638.2 56.6%  
P/CF ratio (eoy) x18.621.3 87.5%  
Price / Book Value ratio x4.64.0 115.0%  
Dividend payout %10.725.7 41.7%   
Avg Mkt Cap Rs m1,696,877493,632 343.8%   
No. of employees `00017.522.7 77.2%   
Total wages/salary Rs m49,02331,068 157.8%   
Avg. sales/employee Rs Th18,028.36,259.0 288.0%   
Avg. wages/employee Rs Th2,798.81,369.8 204.3%   
Avg. net profit/employee Rs Th4,479.5569.7 786.3%   
INCOME DATA
Net Sales Rs m315,784141,961 222.4%  
Other income Rs m6,2321,715 363.4%   
Total revenues Rs m322,016143,676 224.1%   
Gross profit Rs m100,89324,722 408.1%  
Depreciation Rs m12,64810,266 123.2%   
Interest Rs m3,998634 630.6%   
Profit before tax Rs m90,47915,537 582.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m99349 28.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1162,965 408.6%   
Profit after tax Rs m78,46212,921 607.2%  
Gross profit margin %31.917.4 183.5%  
Effective tax rate %13.419.1 70.2%   
Net profit margin %24.89.1 273.0%  
BALANCE SHEET DATA
Current assets Rs m329,53796,837 340.3%   
Current liabilities Rs m178,87084,199 212.4%   
Net working cap to sales %47.78.9 535.9%  
Current ratio x1.81.2 160.2%  
Inventory Days Days7973 107.7%  
Debtors Days Days8398 85.2%  
Net fixed assets Rs m204,766102,552 199.7%   
Share capital Rs m2,399829 289.4%   
"Free" reserves Rs m363,997121,792 298.9%   
Net worth Rs m366,397122,621 298.8%   
Long term debt Rs m14,3615,449 263.5%   
Total assets Rs m614,102218,165 281.5%  
Interest coverage x23.625.5 92.6%   
Debt to equity ratio x00 88.2%  
Sales to assets ratio x0.50.7 79.0%   
Return on assets %13.46.2 216.1%  
Return on equity %21.410.5 203.2%  
Return on capital %24.812.9 192.6%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m44,11881,670 54.0%   
Fx outflow Rs m24,48426,355 92.9%   
Net fx Rs m19,63455,315 35.5%   
CASH FLOW
From Operations Rs m70,82221,444 330.3%  
From Investments Rs m-42,216-18,404 229.4%  
From Financial Activity Rs m-22,854-3,692 619.0%  
Net Cashflow Rs m6,107-1,144 -533.8%  

Share Holding

Indian Promoters % 63.7 25.5 249.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 5.4 95.0%  
FIIs % 23.0 35.3 65.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.3 15.3 54.2%  
Shareholders   133,026 75,885 175.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 23, 2018 03:35 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS